Check back here regularly to find out what's going on with copper-67
October 2021 Iotron Medical appoint Patrick Donahue as CEO
We are pleased to announce the appointment of experience nuclear medicine professional Pat Donahue as CEO with immediate effect to lead our commericlization program for copper-67. Full details in the Press Release below.
August 2021 Collaboration with Canadian Isotope Innovations announced
Together we establish the world's first private sector producer and supplier of copper-67. High quality radioisotope now available bi-weekly in support of radiopharmaceutical development. Press Release outlining the full details of the collaboration available below.
August 2021 First ever Copper-67 User Group meeting hosted by NIDC
Sign up to participate in the first Copper-67 User Group meeting on August 24 - details availalbe here: https://www.isotopes.gov/Join-Our-2021-Isotope-User-Group-Meetings
January 2021 Copper-67 radioisotope available from Iotron Medical
We have now begun routine batch production of copper-67 on a bi-weekly basis. Batches of 2-10 GBq are now available. Contact us at firstname.lastname@example.org for more details. Product specification is available below.
November 2019 Iotron presentation on copper-67
Iotron Medical are presenting at the UK Institute of Physics meeting 'Physics-based Contributions to new Medical Techniques' (PCMT) on November 27 2019. For more information visit the IOP website www.events.iop.org
June 2019 Iotron exhibit at the SNMMI Annual Meeting
Iotron Medical are exhibiting at the Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging, Anaheim Convention Centre, June 22-25 2019. Come and meet the team and learn more about copper-67 at Stand SB4!
February 2019 Focus Group complete review of copper-67 opportunities
A review of the market opportunities for copper-67 has been completed by a 'focus group' comprising leading researchers and clinicians in the field of target radioisotope therapy. This will be used to prioritize our commercialization efforts.
December 2018 Copper-67 to become routinely available from NIDC
The National Isotope Development Centre announces that in 2019 the radioisotope copper-67 will be produced at Argonne in large batches of high specific activity for radiopharmaceutical develpment and testing. Contact Iotron for further details.
November 2018 Third US Patent Granted
A third patent extending the coverage of the Argonne copper-67 produiction technology has been granted by the US Patent Office. The patents can be downloaded from here.
October 2018 Iotron attend EANM'18
Iotron Medical are attending the European Association of Nuclear Mediciane meeting in Dusseldorf to meet with a number of researchers and clinicians in targeted radioisotope therapy to discuss opportunities for copper-67.
February 2017 Japanese Patent Granted
An equivalent patent protecting the copper-67 production technology has been granted in Japan.
May 2016 European Patent Granted
The copper-67 production technology has been further protected by the grant of a European patent which will be validated in Germany, UK, France, Italy and Spain.
April 2016 Second Patent Granted
A second patent covering the Argonne copper-67 production technology has been granted by the US Patent Office.
October 2013 First copper-67 production run at upgraded LEAF accelerator
The collabotrative project between Iotron and Argonne National Laboratory has completed the first production of copper-67 radioisotope on the newly refurbished and upgraded Argonne LEAF linac.
May 2013 License agreement signed for Argonne production technology
Iotron and the Argonne National Laboratory are pleased to announce the signing of a worldwide exclusive license agreement for Iotron to commercialize the patented Argonne copper-67 production technology.
December 2011 Cooperative Research and Development Agreement signed
Iotron and the Argonne National Laboratory have signed a formal agreement to work together on the development of technology to produce the medical radioisotope copper-67. This technology uses a compact electron beam accelerator to make the radioisotope rather than a reactor or high energy proton machine. It opens the possibility to make copper-67, long recognised as having ideal properties for the treatment of cancer, on a commercially sustainable basis for the very first time.
July 2008 First prototype copper-67 target irradiated at RPI
Argonne National Laboratory have successfully made the medical radioisotope copper-67 using an electron beam from the Rensselaer Polytechnic Institute in Troy, New York. The irradiated target was shipped back to the Argonne Laboratory for analysis.
Iotron Medical, a spin-out business of Iotron Industries - providing innovative solutions using electron beam technology for more than 25 years
Canadian Isotope Innovations, operating the most capable radioisotope electron accelerator in North America today
If you have any queries or wish to contact us:
For partnering opportunities:
To buy radioisotope: